Tenax Therapeutics
TENX
9 hedge funds and large institutions have $30.5K invested in Tenax Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 11 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.34% more ownership
Funds ownership: 0.07% → 0.41% (+0.34%)
44% less funds holding
Funds holding: 16 → 9 (-7)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
92% less capital invested
Capital invested by funds: $373K → $30.5K (-$343K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$33.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.68K |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$2.63K |
| 5 |
AF
Allworth Financial
Folsom,
California
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$93K |
| 2 |
Corient Private Wealth
Miami,
Florida
|
-$52.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$51.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$40.7K |
| 5 |
Two Sigma Investments
New York
|
-$39.1K |
TENX Hedge Fund Activity: Q1 2024 in Review
9 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q1 2024, worth a combined $30.5K — down 92% from $373K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TENX and 4 opened new positions — a net loss of 7 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Qube Research & Technologies (QRT), adding an estimated $33.8K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $93K sold.
- 9 institutional investors held Tenax Therapeutics (TENX) as of Q1 2024, down from 16 in Q4 2023.
- Funds reported $30.5K of Tenax Therapeutics stock for Q1 2024, down 92% quarter-over-quarter.
- 4 funds opened new Tenax Therapeutics positions in Q1 2024 and 11 closed out, a net change of -7 holders.
- The largest Tenax Therapeutics buyer in Q1 2024 was Qube Research & Technologies (QRT), an estimated $33.8K added.
- The largest Tenax Therapeutics seller in Q1 2024 was Renaissance Technologies, an estimated $93K sold.
Based on aggregated 13F filings for Q1 2024.